This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Fresenius Medical to Make Huge Investments, Competition Rife
by Zacks Equity Research
Fresenius Medical (FMS) is likely to make huge investments in India and China.
Masimo Gets FDA Clearance for Rad-67 Monitoring Device
by Zacks Equity Research
The clearance will enable Masimo (MASI) to provide portable spot-checking monitoring measurements of oxygen saturation and non-invasive hemoglobin.
Thermo Fisher to Buy Brammer Bio, Tightens Gene Therapy Grip
by Zacks Equity Research
On closure of the acquisition deal, Brammer Bio will be integral to Thermo Fisher's (TMO) pharma services business within its Laboratory Products and Services wing.
BD Remains Confident About LUTONIX DCB Despite FDA Letter
by Zacks Equity Research
Per the recent press release issued by BD (BDX), it seems that the company still has immense confidence on the LUTONIX DCB.
Senseonics Unveils Eversense Bridge Program in the U.S.
by Zacks Equity Research
The Eversense Bridge program aligns with Senseonics' (SENS) strategy of offering innovative yet affordable and hassle-free medical care to diabetic patients.
Quest Diagnostics Grows on New Pacts Amid Reimbursement Issue
by Zacks Equity Research
Quest Diagnostics' (DGX) partnership with UnitedHealthcare to operate as a preferred national laboratory seems strategic for the latter's customers.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
Varian (VAR) Scales New 52-Week High on Solid Prospects
by Zacks Equity Research
The key growth driving factor for Varian (VAR) in the past year has been increasing net sales from major business segments.
HMS Holdings Gains on PI & TPM Solutions, Competition Rife
by Zacks Equity Research
HMS Holdings is consistently boosting margins and profitability on product-yield enhancements and process improvements.
Here's Why You Should Retain Ecolab Stock in Your Portfolio
by Zacks Equity Research
A solid guidance for 2019 and broad product spectrum will provide Ecolab (ECL) a competitive edge in the MedTech space.
Top Ranked Momentum Stocks to Buy for March 21st
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 21st
Abbott's (ABT) MitraClip COAPT Trial Shows Favorable Results (revised)
by Zacks Equity Research
The published data sets prove that Abbott's (ABT) MitraClip ensures the sustenance of long-term quality of life for patients of secondary or functional mitral regurgitation (MR).
Stryker (SYK) Scales a New 52-Week High on Solid Prospects
by Zacks Equity Research
The key growth-driving factor for Stryker (SYK) in the past year has been increasing net sales from each of its three major business segments.
Abbott's (ABT) MitraClip COAPT Trial Shows Favorable Results (Revised)
by Zacks Equity Research
The published data sets prove that Abbott's (ABT) MitraClip ensures the sustenance of long-term quality of life for patients of secondary or functional MR.
Boston Scientific (BSX) Rides on Acquisitions, Innovation
by Zacks Equity Research
Boston Scientific (BSX) takes a big leap forward by closing the buyout of Millipede and inking a deal to purchase BTG plc.
Boston Scientific's EP Arm Gets a Lift From Study Success
by Zacks Equity Research
The positive result regarding Boston Scientific's (BSX) LUMINIZE RF Balloon Catheter is expected to help the company further advance with the procedures to clinch a CE Mark for the instrument.
Abbott's (ABT) MitraClip COAPT Trial Shows Favorable Results
by Zacks Equity Research
The published data sets prove that Abbott's (ABT) MitraClip ensures the sustenance of long-term quality of life for patients of secondary or functional mitral regurgitation (MR).
Omnicell's Global Expansion on Track, Stiff Competition Ails
by Zacks Equity Research
Although Omnicell (OMCL) is steadily expanding in the Middle East and South African belts, it sees a greater uptake of technologies across other regions of the world.
Integra's Duragen Secures Japanese Nod to Drive Global Growth
by Zacks Equity Research
Despite facing adverse foreign exchange volatility across its international business, Integra LifeSciences (IART) can successfully eye certain key developments on foreign shores.
Here's Why You Should Buy Masimo (MASI) Stock Right Now
by Zacks Equity Research
Masimo (MASI) announces CE marking of its Next Generation SedLine brain function monitoring for pediatric patients.
Abbott (ABT) Gets FDA Approval for Expanded Use of MitraClip
by Zacks Equity Research
The FDA approval is expected to strengthen Abbott's (ABT) structural heart business.
Tandem Diabetes (TNDM) Hits a 52-Week High on Solid Prospects
by Zacks Equity Research
Tandem Diabetes Care's (TNDM) growth in pump shipments drives the top line significantly.
Cardiovascular Systems Gains on Global Growth & Innovation
by Zacks Equity Research
Cardiovascular Systems (CSII) hopes that new product menu will deliver minimum 10% growth in its core business during the second half of fiscal 2019.
Edwards Lifesciences Makes Investments in Heart Failure Space
by Zacks Equity Research
The two transactions align with Edwards Lifesciences' (EW) goal of making the most innovative medical care available to patients of structural heart disease.
Haemonetics' Plasma Unit Grows, Global Expansion on Track
by Zacks Equity Research
Haemonetics' (HAE) Plasma arm steadily witnesses solid growth in the fiscal third quarter on 16% revenue rise at constant currency.